CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: CD9, a member of the tetraspanin superfamily, is a tumor suppressor in many malignancies. The aim of this study was to evaluate the immunohistochemical expression of CD9 in colorectal carcinomas (CRCs) and determine clinicopathological and prognostic significance of its expression. Methods: The CD9 expression status of 305 CRCs was evaluated using a semi-quantitative scoring system in tumor cells (T-CD9) and immune cells (I-CD9) by classifying the results as high and low expression. Results: High T-CD9 (T-CD9 [+]) expression was detected in 175 samples (57.6%) and high I-CD9 (I-CD9 [+]) expression was detected in 265 samples (86.9%). Using Kaplan-Meier survival analysis, the T-CD9 (+) group showed a tendency for better disease-free survival (DFS) (p = .057). In left-sided tumors, DFS was significantly longer in the T-CD9 (+) group (p = .021) but no statistical significance was observed with right-sided tumors (p = .453). I-CD9 (+) CRCs significantly correlated with well/moderately differentiation (p = .014). In Kaplan-Meier analysis, the I-CD9 (+) group had a tendency towards worse DFS compared to the I-CD9 (–) group (p = .156). In combined survival analysis of T-CD9 and I-CD9, we found that the longest DFS was among patients in the T-CD9 (+)/I-CD9 (–) group, whereas the T-CD9 (–)/I-CD9 (+) group showed the shortest DFS (p = .054). Conclusions: High expression of T-CD9 was associated with a favorable DFS, especially in left-sided CRCs. Combined evaluation of T-CD9 and I-CD9 is required to determine the comprehensive prognostic effect of CD9 in CRCs.
Abstract
Background: CD9, a member of the tetraspanin superfamily, is a tumor suppressor in many malignancies. The aim of this study was to evaluate the immunohistochemical expression of CD9 in colorectal carcinomas (CRCs) and determine clinicopathological and prognostic significance of its expression. Methods: The CD9 expression status of 305 CRCs was evaluated using a semi-quantitative scoring system in tumor cells (T-CD9) and immune cells (I-CD9) by classifying the results as high and low expression. Results: High T-CD9 (T-CD9 [+]) expression was detected in 175 samples (57.6%) and high I-CD9 (I-CD9 [+]) expression was detected in 265 samples (86.9%). Using Kaplan-Meier survival analysis, the T-CD9 (+) group showed a tendency for better disease-free survival (DFS) (p = .057). In left-sided tumors, DFS was significantly longer in the T-CD9 (+) group (p = .021) but no statistical significance was observed with right-sided tumors (p = .453). I-CD9 (+) CRCs significantly correlated with well/moderately differentiation (p = .014). In Kaplan-Meier analysis, the I-CD9 (+) group had a tendency towards worse DFS compared to the I-CD9 (–) group (p = .156). In combined survival analysis of T-CD9 and I-CD9, we found that the longest DFS was among patients in the T-CD9 (+)/I-CD9 (–) group, whereas the T-CD9 (–)/I-CD9 (+) group showed the shortest DFS (p = .054). Conclusions: High expression of T-CD9 was associated with a favorable DFS, especially in left-sided CRCs. Combined evaluation of T-CD9 and I-CD9 is required to determine the comprehensive prognostic effect of CD9 in CRCs.
참고문헌 (32)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Dalerba P, "Immunology and immunotherapy of colorectal cancer", Crit Rev Oncol Hematol, 46, pp.33~57 (2003)
- Kim Y, "Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas", PLoS One, 10, pp.e0122183~ (2015)
- Murayama Y, "Novel CD9-targeted therapies in gastric cancer", World J Gastroenterol, 21, pp.3206~3213 (2015)
- Le Naour F, "Profiling of the tetraspanin web of human colon cancer cells", Mol Cell Proteomics, 5, pp.845~857 (2006)
- Erovic BM, "Motility-related protein-1", CD9 expression in head and neck squamous cell carcinoma, 2003, pp.25, 848~857
- Regina Todeschini A, "Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains", Biochim Biophys Acta, 1780, pp.421~433 (2008)
- Kwon HJ, "Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance", Pathol Res Pract, 210, pp.285~290 (2014)
- Huang CI, "Correlation of reduction in MRP-1", CD9 and KAI1, Am J Pathol, pp.1998, 153[DOI]
- Chen Z, "Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma", World J Surg Oncol, 9, pp.43~ (2011)
- Houle CD, "Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression", Gynecol Oncol, 86, pp.69~78 (2002)
- Furuya M, "Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets", Cancer Res, 65, pp.2617~2625 (2005)
- Yin M, "Osteopontin promotes the invasive growth of melanoma cells by activating integrin alphavbeta3 and down-regulating tetraspanin CD9", Am J Pathol, 184, pp.842~858 (2014)
- Ikeyama S, "Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1", CD9) DNA, 1993, pp.177, 1231~1237
- Takeda T, "Adenoviral transduction of MRP-1", CD9 and KAI1, Cancer Res, pp.2007, 67[DOI]
- Ovalle S, "The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells", Int J Cancer, 121, pp.2140~2152 (2007)
- Salgado R, "The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
- Iacopetta B, "Are there two sides to colorectal cancer?", Int J Cancer, 101, pp.403~408 (2002)
- Lee JH, "Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9", CD82 and suppresses the Wnt, Gut, pp.2010, 59[DOI]
- Sho M, "Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer", Int J Cancer, 79, pp.509~516 (1998)
- Boucheix C, "Tetraspanins and malignancy", Expert Rev Mol Med, 2001, pp.1~17 (2001)
- Hashida H, "Integrin alpha3 expression as a prognostic factor in colon cancer : association with MRP-1", CD9 and KAI1, Int J Cancer, pp.2002, 97[DOI]
- Miyake M, "Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1", CD9) gene delivery, 2000, pp.19, 5221~5226
- Mori M, "Motility related protein 1 (MRP1", CD9) expression in colon cancer, 1998, pp.4, 1507~1510
- Okochi H, "Expression of tetraspans transmembrane family in the epithelium of the gastrointestinal tract", J Clin Gastroenterol, 29, pp.63~67 (1999)
- Hori H, "CD9 expression in gastric cancer and its significance", J Surg Res, 117, pp.208~215 (2004)
- Soyuer S, "Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy", Pathol Res Pract, 206, pp.607~610 (2010)
- Bae JM, "Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway", Arch Pathol Lab Med, 140, pp.406~412 (2016)
- Armaghany T, "Genetic alterations in colorectal cancer", Gastrointest Cancer Res, 5, pp.19~27 (2012)
- Bruno A, "A think tank of TINK", TANKs: tumor-infiltrating, J Natl Cancer Inst, pp.2014, 106[DOI]
- Wang YD, "Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells", Oncogene, 21, pp.2584~2592 (2002)
- Sugiura T, "Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion: evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2)", J Cell Biol, 146, pp.1375~1389 (1999)